Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

BioMarin ends investment in Inozyme acquisition

PUBLIC · BMRNAug 10, 2026•about 2 hours ago

Acquiring Company

BioMarin

Acquired Company

Inozyme Pharma

San Rafael

BostonBiotechnologyHealth CareMedicalGeneticsTherapeuticsHealth CareTherapeuticsPharmaceutical

Description

BioMarin has decided to discontinue the development of BMN 401, part of its $270 million acquisition of Inozyme Pharma. The asset proved disappointing in clinical trials for ENPP1 deficiency. The company has no active programs remaining in this indication or related diseases. Despite this setback, BioMarin reported positive earnings and raised its revenue guidance for the year.

Company Information

Company

BioMarin

Location

San Rafael, California, United States

About

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Predictive Intelligence

Strategic

ML-powered predictions for BioMarin's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Inozyme Pharma?

Inozyme Pharma was acquired by BioMarin, based in San Rafael. The deal was reported on August 10, 2026. Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. BioMarin is publicly traded (BMRN) and operates in Biotechnology.

When did BioMarin acquire Inozyme Pharma?

BioMarin's acquisition of Inozyme Pharma was reported on August 10, 2026. BioMarin has decided to discontinue the development of BMN 401, part of its $270 million acquisition of Inozyme Pharma. The asset proved disappointing in clinical trials for ENPP1 deficiency. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Inozyme Pharma do?

Inozyme Pharma is a USA-based biopharma company focused on developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. The company aims to address significant unmet needs in patients suffering from these conditions. It is privately held, operating in Health Care, and is based in Boston.